VRTX:NGS-Vertex Pharmaceuticals Incorporated (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 485.37

Change

0.00 (0.00)%

Market Cap

USD 21.38B

Volume

0.70M

Analyst Target

USD 306.43
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

-6.33 (-0.55%)

USD 127.14B
ALNY Alnylam Pharmaceuticals Inc

+4.09 (+1.51%)

USD 34.71B
ARGX argenx NV ADR

-15.72 (-2.92%)

USD 32.33B
MRNA Moderna Inc

+2.82 (+4.08%)

USD 26.25B
SMMT Summit Therapeutics PLC

-3.26 (-11.06%)

USD 23.47B
BGNE BeiGene Ltd

+1.06 (+0.54%)

USD 21.94B
RPRX Royalty Pharma Plc

-0.02 (-0.07%)

USD 16.45B
BMRN Biomarin Pharmaceutical Inc

+0.69 (+0.99%)

USD 16.16B
UTHR United Therapeutics Corporatio..

+0.04 (+0.01%)

USD 15.09B
PCVX Vaxcyte Inc

+2.51 (+2.20%)

USD 14.27B

ETFs Containing VRTX

DCCHAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

+0.23 (+0.23%)

USD 0.07B
DCUSAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

N/A
DCEUAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

N/A
DCGBAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

N/A
BBH VanEck Biotech ETF 9.55 % 0.35 %

-0.34 (0.23%)

USD 0.46B
MSGR 8.22 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 7.99 % 0.00 %

+0.14 (+0.23%)

N/A
CURG:LSE VanEck Genomics and Healt.. 7.96 % 0.00 %

+0.15 (+0.23%)

USD 7.21M
BTEC:SW iShares Nasdaq US Biotech.. 7.95 % 0.00 %

-0.01 (0.23%)

N/A
IBBQ Invesco Nasdaq Biotechnol.. 7.73 % 0.00 %

-0.06 (0.23%)

USD 0.04B
2B70:F iShares NASDAQ US Biotech.. 7.60 % 0.00 %

-0.02 (0.23%)

USD 0.52B
2B70:XETRA iShares Nasdaq US Biotech.. 7.60 % 0.00 %

+0.04 (+0.23%)

USD 0.52B
BIS ProShares UltraShort Nasd.. 7.21 % 0.95 %

+0.10 (+0.23%)

USD 3.29M
UBIO 6.52 % 0.95 %

N/A

N/A
LIFE-B:CA Evolve Global Healthcare .. 5.49 % 0.00 %

-0.31 (0.23%)

N/A
ZWHC:CA BMO Covered Call Health C.. 5.16 % 0.00 %

N/A

N/A
BIB ProShares Ultra Nasdaq Bi.. 5.05 % 0.95 %

-0.29 (0.23%)

USD 0.09B
LIFE-U:CA Evolve Global Healthcare .. 5.00 % 0.00 %

N/A

N/A
XGES:LSE Xtrackers MSCI Genomic He.. 4.94 % 0.00 %

+0.27 (+0.23%)

N/A
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.91 % 0.00 %

+0.26 (+0.23%)

N/A
XNNS:LSE Xtrackers MSCI Innovation.. 4.83 % 0.00 %

+0.35 (+0.23%)

N/A
XNNV:LSE Xtrackers MSCI Innovation.. 4.83 % 0.00 %

+0.36 (+0.23%)

N/A
XDG3:XETRA Xtrackers MSCI Global SDG.. 4.77 % 0.00 %

-0.12 (0.23%)

USD 0.14B
XNNV:XETRA Xtrackers MSCI Innovation.. 4.76 % 0.00 %

+0.31 (+0.23%)

N/A
SAMM The Advisors’ Inner .. 4.15 % 0.00 %

+0.06 (+0.23%)

N/A
XDGI:XETRA Xtrackers MSCI Global SDG.. 3.70 % 0.00 %

+0.25 (+0.23%)

USD 0.02B
CBUF:XETRA iShares MSCI World Health.. 3.45 % 0.00 %

-0.03 (0.23%)

USD 1.13B
HEAL:CA 3.39 % 0.00 %

N/A

N/A
CDNA:CA 2.94 % 0.00 %

N/A

N/A
BIOT:SW L&G Pharma Breakthrough U.. 2.68 % 0.00 %

N/A

N/A
ETLI:XETRA L&G Pharma Breakthrough U.. 2.64 % 0.00 %

+0.04 (+0.23%)

USD 0.02B
UPWD 2.43 % 0.00 %

N/A

N/A
POWA Invesco Bloomberg Pricing.. 2.11 % 0.00 %

-0.33 (0.23%)

N/A
XLVE:CA Mulvihill U.S. Health Car.. 1.93 % 0.00 %

+0.18 (+0.23%)

N/A
MVEA:SW iShares Edge MSCI USA Min.. 1.62 % 0.00 %

+0.03 (+0.23%)

USD 0.39B
MVEA:XETRA iShares Edge MSCI USA Min.. 1.56 % 0.00 %

+0.02 (+0.23%)

USD 0.32B
ESMV iShares ESG MSCI USA Min .. 1.51 % 0.00 %

-0.08 (0.23%)

USD 0.01B
MVEW:XETRA iShares Edge MSCI World M.. 1.37 % 0.00 %

+0.01 (+0.23%)

USD 0.78B
MVEC:SW iShares Edge MSCI World M.. 1.37 % 0.00 %

+0.04 (+0.23%)

USD 0.17B
MVEW:SW iShares Edge MSCI World M.. 1.37 % 0.00 %

+0.06 (+0.23%)

USD 0.61B
MVWE:SW iShares Edge MSCI World M.. 1.37 % 0.00 %

N/A

USD 0.07B
MVEW:LSE iShares Edge MSCI World M.. 1.33 % 0.00 %

+0.02 (+0.23%)

USD 0.61B
FLXU:SW Franklin U.S. Equity UCIT.. 1.17 % 0.00 %

+0.27 (+0.23%)

N/A
FLXU:XETRA Franklin LibertyShares IC.. 1.06 % 0.00 %

+0.38 (+0.23%)

USD 0.18B
THNZ:XETRA L&G Global Thematic ESG E.. 1.03 % 0.00 %

+0.12 (+0.23%)

N/A
SMRT:PA 0.59 % 0.00 %

N/A

N/A
SM8T:XETRA Amundi Index Solutions - .. 0.58 % 0.00 %

+2.70 (+0.23%)

USD 0.04B
SMRU:PA Amundi Index Solutions - .. 0.58 % 0.00 %

+4.70 (+0.23%)

USD 3.47M
DEF 0.00 % 0.59 %

N/A

N/A
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

-0.57 (0.23%)

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

-0.26 (0.23%)

USD 7.64B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

+0.04 (+0.23%)

USD 0.09B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

-0.05 (0.23%)

N/A
FTXH First Trust Nasdaq Pharma.. 0.00 % 0.60 %

-0.14 (0.23%)

USD 0.02B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.03 (+0.23%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.04 (+0.23%)

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

+5.70 (+0.23%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.02 (+0.23%)

N/A
VLQ:CA 0.00 % 0.40 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

-0.33 (0.23%)

N/A
ZBIO 0.00 % 0.95 %

N/A

N/A
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

-0.42 (0.23%)

CAD 0.27B
HWWA:LSE HSBC Multi Factor Worldwi.. 0.00 % 0.00 %

+0.14 (+0.23%)

N/A
SMRG:LSE 0.00 % 0.00 %

N/A

N/A
SMRU:LSE Amundi Index Solutions - .. 0.00 % 0.00 %

+5.14 (+0.23%)

N/A
HWWD:LSE HSBC Multi Factor Worldwi.. 0.00 % 0.00 %

+0.24 (+0.23%)

N/A
VMOM:LSE 0.00 % 0.00 %

N/A

N/A
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

-0.03 (0.23%)

N/A
FLXU:F Franklin LibertyShares IC.. 0.00 % 0.00 %

-0.07 (0.23%)

N/A
SM8T:F Amundi Index Solutions - .. 0.00 % 0.00 %

+1.30 (+0.23%)

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
ZINN:CA 0.00 % 0.00 %

N/A

N/A
NVQ 0.00 % 0.00 %

N/A

N/A
NDOW 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.29% 71% C- 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.29% 71% C- 79% B-
Trailing 12 Months  
Capital Gain 39.11% 75% C 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.11% 74% C 83% B
Trailing 5 Years  
Capital Gain 173.37% 88% B+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 173.37% 87% B+ 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 17.68% 71% C- 75% C
Dividend Return 17.68% 71% C- 74% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.12% 92% A 68% D+
Risk Adjusted Return 67.69% 98% N/A 87% B+
Market Capitalization 21.38B 100% F 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 32.57 21% 29%
Price/Book Ratio 8.48 16% 13%
Price / Cash Flow Ratio 35.42 3% 8%
Price/Free Cash Flow Ratio 258.90 0% 1%
Management Effectiveness  
Return on Equity -3.24% 94% 55%
Return on Invested Capital 18.99% 89% 87%
Return on Assets 12.96% 99% 97%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.